Listen to this article in summarized format
Loading...
××
Subscribe to
Unlock AI Briefing and Premium Content
New Year Offer 24 Hours Left
Subscribe NowAlready a member? Sign In
What's Included
- Exclusive Stories
- Daily ePaper Access
- Smart Market Tools
- Curated Investment Ideas
- Ad-lite Experience
Subscription
Mumbai: Abbott has entered into a strategic collaboration with Novo Nordisk India to commercialise another brand of Novo’s blockbuster GLP-1 drug Ozempic (semaglutide). The partnership, which comes less than a month ahead of semaglutide’s patent expiry in India, is a key move by the Danish drug innovator to expand access in India beyond the regions it currently serves by leveraging Abbott’s distribution network.
Abbott’s drug will be marketed under the brand name Extensior and is indicated for people living with type 2 diabetes.
Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.
Extensior will be introduced in India as part of Abbott’s expanding portfolio of advanced diabetes solutions and is expected to be available for Indian patients soon, Abbott said in a statement.
“India is facing one of the world’s fastest-growing diabetes burdens, and addressing this challenge requires continuous innovation and strong partnerships,” said Kartik Rajendran, managing director, Abbott India.
“The launch of Extensior builds on Abbott’s long-standing focus on holistic diabetes management—from medicines to diagnostics, and from continuous glucose monitoring to diabetes-specific nutrition,” he added.
“Our partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India,” said Vikrant Shrotriya, managing director, Novo Nordisk India.
More than 100 million individuals in India live with diabetes and this is projected to surge 50% to more than 150 million by 2050 driven by rapid urbanisation, aging populations, increasing obesity and lifestyle changes.
Cardiovascular and kidney issues now account for much of the long-term risk faced by people living with type 2 diabetes. In India, about 43% of individuals with diabetes remain undiagnosed, limiting opportunities for early intervention.
Extensior will be available in the FlexTouch Pen—a once-weekly pen device that provides precise dosing in 0.25 mg, 0.5 mg and 1 mg dose strengths.
Abbott’s drug will be marketed under the brand name Extensior and is indicated for people living with type 2 diabetes.
Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.
Extensior will be introduced in India as part of Abbott’s expanding portfolio of advanced diabetes solutions and is expected to be available for Indian patients soon, Abbott said in a statement.
“India is facing one of the world’s fastest-growing diabetes burdens, and addressing this challenge requires continuous innovation and strong partnerships,” said Kartik Rajendran, managing director, Abbott India.
“The launch of Extensior builds on Abbott’s long-standing focus on holistic diabetes management—from medicines to diagnostics, and from continuous glucose monitoring to diabetes-specific nutrition,” he added.
“Our partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India,” said Vikrant Shrotriya, managing director, Novo Nordisk India.
More than 100 million individuals in India live with diabetes and this is projected to surge 50% to more than 150 million by 2050 driven by rapid urbanisation, aging populations, increasing obesity and lifestyle changes.
Cardiovascular and kidney issues now account for much of the long-term risk faced by people living with type 2 diabetes. In India, about 43% of individuals with diabetes remain undiagnosed, limiting opportunities for early intervention.
Extensior will be available in the FlexTouch Pen—a once-weekly pen device that provides precise dosing in 0.25 mg, 0.5 mg and 1 mg dose strengths.
